Product Description
Acetaminophen is a widely used nonprescription analgesic and antipyretic medication for mild-to-moderate pain and fever. Harmless at low doses, acetaminophen has direct hepatotoxic potential when taken as an overdose and can cause acute liver injury and death from acute liver failure. Even in therapeutic doses, acetaminophen can cause transient serum aminotransferase elevations. Acetaminophen is a p-aminophenol derivative with analgesic and antipyretic activities. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Acetaminophen)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Company: Johnson & Johnson
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, Canada, China, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Poland, Qatar, South Korea, Spain, United Kingdom, United States
Active Clinical Trial Count: 32
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Arthralgia|Bunion|Common Cold|Influenza, Human|Low Back Pain|Lupus Erythematosus, Systemic|Lupus Nephritis|Osteoarthritis|Osteoarthritis, Hip|Osteoarthritis, Knee|Pain Unspecified|Pain, Postoperative|Toothache
Phase 2: Chronic Pain|Ductus Arteriosus, Patent|Multiple Myeloma|Type 1 Diabetes
Phase 1: Arthritis|Back Pain|Cancer Pain|Depressive Disorder|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Headache|Healthy Volunteers|Lymphoma, Non-Hodgkin|Muscle Cramp|Obesity|Other|Overweight
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-505226-33-00 |
PTG007DM1preTREG001 | P2 |
Recruiting |
Type 1 Diabetes |
2032-10-31 |
55% |
2025-05-02 |
Treatments |
NCT04702256 |
OBILUP | P3 |
Recruiting |
Lupus Erythematosus, Systemic|Lupus Nephritis |
2031-12-01 |
2021-12-11 |
||
jRCT2051250248 |
jRCT2051250248 | P1 |
Not yet recruiting |
Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma |
2030-06-06 |
|||
2022-503063-15-00 |
CARTemis-1 | P2 |
Not yet recruiting |
Multiple Myeloma |
2030-03-31 |
2025-05-02 |
Treatments |
|
2024-510792-38-01 |
2024-510792-38-01 | P3 |
Withdrawn |
Pain Unspecified |
2029-03-01 |
2025-05-02 |
Treatments |
|
NCT07225140 |
AFT-MX-16p | P3 |
Not yet recruiting |
Acute Pain|Pain, Postoperative |
2027-10-01 |
50% |
2026-07-02 |
Primary Endpoints |
2025-521578-32-00 |
DI-OR-PA | P3 |
Not yet recruiting |
Low Back Pain |
2027-03-31 |
|||
NCT07225634 |
AFT-MXIV-08p | P3 |
Not yet recruiting |
Acute Pain |
2027-03-01 |
5% |
2026-07-02 |
|
NCT05742763 |
PRPNSAIDsKOA | P2 |
Recruiting |
Osteoarthritis, Knee|Chronic Pain |
2026-12-31 |
2024-04-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
2023-503209-13-00 |
2023-503209-13-00 | P2 |
Recruiting |
Ductus Arteriosus, Patent |
2026-03-30 |
2025-05-02 |
Treatments |
|
NCT07269756 |
HRS-7535-110 | P1 |
Completed |
Overweight|Obesity |
2026-03-08 |
2026-04-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06863636 |
PRECEDENT | P3 |
Recruiting |
Osteoarthritis, Hip|Arthralgia|Osteoarthritis, Knee |
2025-10-30 |
2025-03-08 |
Primary Endpoints|Treatments |
|
NCT05831449 |
CPL-01-302 | P3 |
Completed |
Pain, Postoperative|Bunion |
2025-09-25 |
8% |
2026-05-01 |
Primary Endpoints |
NCT05118672 |
RESFRIN | P3 |
Completed |
Common Cold |
2025-08-26 |
2025-09-23 |
||
2022-003559-32 |
2022-003559-32 | P3 |
Completed |
Influenza, Human |
2024-12-04 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12621000694819 |
ACTRN12621000694819 | P3 |
Completed |
Osteoarthritis |
2024-09-06 |
2025-11-20 |
Treatments |
|
NCT05761574 |
CCSPAA005199 | P3 |
Completed |
Toothache |
2024-05-17 |
2024-07-23 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20234112 |
CTR20234112 | P1 |
Completed |
Chronic Pain|Cancer Pain |
2024-04-08 |
2025-04-29 |
Primary Completion Date |
|
NCT04123717 |
IRB 16206/16 | P1 |
Completed |
Other |
2024-03-07 |
2024-08-15 |
Primary Endpoints |
|
2024-510792-38-00 |
2024-510792-38-00 | P3 |
Withdrawn |
Pain Unspecified |
2029-03-01 |
2025-05-02 |
Treatments |
|
NCT07429032 |
NCT07429032 | P1 |
Completed |
Overweight|Obesity |
2025-11-26 |
2026-02-25 |
Primary Endpoints|Treatments |
|
CTR20250869 |
CTR20250869 | P3 |
Completed |
Pain, Postoperative |
2025-11-10 |
2026-01-11 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05813847 |
CPL-01-301 | P3 |
Completed |
Pain, Postoperative |
2025-09-15 |
8% |
2026-05-01 |
Primary Endpoints|Treatments |
NCT06855576 |
NCT06855576 | P1 |
Completed |
Healthy Volunteers|Pain Unspecified |
2025-04-17 |
2025-05-07 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
2013-001842-33 |
PreParaS | P2 |
Completed |
Unknown |
2024-08-08 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |